Oncology Student Loans: High Debt, High Salary, and Why Refinancing Usually Wins

A newly minted hematology-oncology fellow finishing a 3-year fellowship carries an average of $287,000 in medical school debt — and has spent the last eight years earning resident and fellow stipends while that balance quietly compounded. By the time they sign an attending contract, they're often staring at a number that's grown by $40,000–$60,000 since graduation. The good news: oncology attending salaries are among the highest in medicine. The real question is whether you're using the right strategy to pay it off.

This guide breaks down the full oncology student loans repayment landscape — including when refinancing wins, when PSLF beats it, and how to run the math for your specific situation.

The Oncology Debt Picture: What the Numbers Actually Look Like

Medical oncologists complete 3 years of internal medicine residency followed by a 3-year hematology-oncology fellowship. That's a minimum of 6 years post-graduation before attending income kicks in. Radiation oncologists and surgical oncologists have different training timelines but similar debt accumulation patterns.

The AAMC's 2023 Medical School Graduation Questionnaire pegged median medical school debt at $200,000 for graduating students who borrowed — but that's across all specialties. Physicians who attended higher-cost private schools or took on additional graduate debt, especially those feeding into competitive oncology fellowships, often graduate with $250,000–$320,000 in federal loans.

Here's what the debt trajectory looks like in practice over those six years of training:

• Starting balance at graduation: $260,000
• IBR payments during residency/fellowship (~$300–$400/month): Mostly cover interest, but not quite
• Unpaid interest capitalizes: Balance grows to roughly $295,000–$310,000
• Starting attending salary (hematology-oncology, employed): $350,000–$450,000 per MGMA 2023 data
• Radiation oncology median compensation: approximately $486,000 (Medscape Physician Compensation Report 2023)

That income-to-debt ratio changes everything. At $400,000 in annual income with $300,000 in loans, your debt-to-income ratio sits below 1:1. That's where aggressive private refinancing typically crushes the 20–25 year federal IDR path.

Oncology Student Loans Repayment Strategy: The Three Paths

Path 1: Refinance as an Attending

For most oncology attendings in private practice or for-profit hospital settings, refinancing wins — and it usually isn't close.

Here's the math: The federal IBR plan (the current default for most physicians after SAVE was vacated by the 8th Circuit in March 2026) calculates payments at 10% of discretionary income for new borrowers. At a $400,000 attending salary, your IBR payment lands around $2,800–$3,200 per month. Sounds manageable. But you're stretching repayment across 20–25 years and interest keeps accruing the whole time.

Refinancing to a 5-year term at 5.5–6.5% fixed rate (rates available from Juno, ELFI, and others as of 2026) on a $300,000 balance means paying roughly $5,700–$6,200 per month — but your debt vanishes in 5 years with total interest in the $80,000–$100,000 range. Compare that to $200,000+ under a prolonged IBR strategy with no forgiveness. The choice becomes obvious.

Consider a radiation oncologist earning $480,000 with zero interest in academic medicine. Refinance to a 7-year term and your monthly payment sits around $4,100–$4,400, debt's gone by year 7, and you're looking at $110,000–$130,000 in total interest. That's real money saved.

Refinancing makes the most sense when:

• You're in private practice or any for-profit employment setting
• Your salary exceeds $350,000
• You have no realistic path to 10 years of nonprofit qualifying employment
• Fellowship training years won't count toward PSLF

→ Dig into the details at best student loan refinancing for doctors 2026

Path 2: PSLF for Academic Oncologists

PSLF is the exception, not the rule, in oncology — but it's a genuinely powerful tool for physicians who train and work at academic medical centers.

Here's where the math gets compelling: If you completed your internal medicine residency and hematology-oncology fellowship at a qualifying 501(c)(3) institution — Memorial Sloan Kettering, MD Anderson's academic affiliate network, Mayo Clinic, a university hospital — those 6 years count toward your 10-year PSLF clock. That means you need only 4 more years as an attending at a qualifying employer to hit forgiveness.

Four years of IBR payments at a $380,000 attending salary totals roughly $130,000–$150,000 before the remaining balance — potentially $150,000–$200,000 — gets wiped out tax-free under current PSLF rules.

You're looking at a $150,000–$200,000 advantage over the refinancing path. PSLF wins decisively.

PSLF works best when:

• You trained at a qualifying nonprofit hospital system
• You're staying at an academic cancer center or university hospital
• You've already banked 4–6 qualifying years from training
• Your attending employer qualifies (verify on the PSLF employer list for 2026)

Here's the trap oncologists fall into: assuming their fellowship institution automatically qualifies their attending contract. Some cancer centers operate as professional corporations under a university umbrella. Don't assume. Run the PSLF employer eligibility check before anchoring your career decision on PSLF.

Path 3: Hybrid — Refinance After PSLF Falls Through

The worst scenario? Staying on IBR for 5–7 years as an attending at a for-profit system, making substantial income-driven payments that don't lead to forgiveness, then refinancing. You've paid the downside of both strategies without getting the upside of either.

Say you're a hematology-oncology attending who started at a nonprofit hospital and switched to private practice after 3 years of attending work (9 years total with training). You've fallen just short of PSLF eligibility. At that point, refinance immediately to a 5–7 year term. Don't linger on IBR hoping circumstances change.

For a deeper look at how student loan refinancing for hematologists and oncologists plays out across different settings, consider comparing your specific debt payoff scenarios.

The 2026 Policy Landscape: What Changes for Oncology Residents Right Now

If you're currently a hematology-oncology fellow or finishing your internal medicine residency, the repayment environment has shifted significantly:

• SAVE is dead. The 8th Circuit vacated the SAVE plan on March 10, 2026. Any borrower enrolled in SAVE has been or will be moved to IBR. That interest subsidy that made SAVE attractive during training? Gone.
• IBR is the default. New borrowers entering repayment get enrolled in IBR. Payments run 10% of discretionary income for borrowers who took loans after July 1, 2014.
• PAYE is closed. PAYE shut to new enrollees as of July 1, 2026. If you're a newer borrower, that option doesn't exist.
• RAP (Repayment Assistance Plan) applies to loans first disbursed on or after July 1, 2026 — not relevant to most current residents unless fellowship required new borrowing.

For current fellows, the practical takeaway: IBR during training remains the right call if you're targeting PSLF. Keep payments low, preserve your qualifying months, stay in the federal system. If you're planning to refinance at attending transition, timing matters — refinance after you've locked in your attending position and verified it's not a qualifying employer.

Subspecialty Matters: Hematology-Oncology vs. Radiation vs. Surgical Oncology

Not all oncologists face the same debt-to-income equation. Here's how they stack up:

Hematology-Oncology (Medical Oncology)

• Fellowship: 3 years post-IM (6 total)
• Median attending compensation: $350,000–$430,000 (MGMA 2023)
• Debt-to-income at fellowship completion: often 0.7:1 to 0.9:1
• Refinancing typically wins in private practice

Radiation Oncology

• Residency: 4–5 years
• Median compensation: $480,000–$510,000 (Medscape 2023)
• Shorter path to attending; DTI usually under 0.6:1
• Strongest refinancing case across all oncology subspecialties

Surgical Oncology

• General surgery residency (5 years) + fellowship (1–2 years)
• Median compensation: $380,000–$460,000
• 7–8 years of training; debt accumulates significantly
• Worth running PSLF math if academic surgery is your plan

A Specific Oncology Repayment Example

Dr. Priya S., Hematology-Oncology Attending

• Starting balance at fellowship completion: $305,000
• IBR payments during 6 years of training: ~$30,000 total
• Attending salary: $410,000 at a for-profit cancer center
• Refinance option: 7-year term, 6.0% fixed → $4,450/month
• Total interest paid: ~$68,000
• Debt-free at year 7 of attending career

Compare this to staying on IBR:

• IBR payment at $410K income: ~$3,000/month
• 20-year repayment: ~$720,000 total paid (interest stacks up fast)
• No forgiveness (for-profit employer)
• Net cost premium vs. refinancing: $300,000+

Refinancing saves Dr. Priya over $300,000 and eliminates the debt 13 years sooner. That's the typical payoff for a high-earning oncologist in private practice.

Ready to crunch your own numbers? Start with the MedDebt Refinancing Tool or take the 2-minute quiz for a personalized recommendation.

Frequently Asked Questions: Oncology Student Loans Repayment

Should oncology attendings refinance their student loans? Most oncology attendings in private practice should refinance. With salaries typically above $350,000 and loan balances in the $250,000–$320,000 range, the debt-to-income ratio favors aggressive private refinancing over long-term federal IDR. Academic oncologists with PSLF qualifying employment from training are the exception — model PSLF before refinancing.

How does PSLF work for oncology fellows? Fellowship months at a qualifying 501(c)(3) hospital count toward PSLF's 120-payment requirement. A fellow who finished 3 years of IM residency and 3 years of fellowship at nonprofit institutions starts their attending career with 72 qualifying payments already in the bank — needing only 48 more (4 years) at a qualifying employer to reach forgiveness.

What is the best repayment plan for hematology-oncology fellows in 2026? IBR is the default and best option for fellows pursuing PSLF. SAVE was vacated in March 2026 and is off the table. PAYE closed to new enrollees July 1, 2026. Fellows not pursuing PSLF should keep payments low on IBR during training and refinance immediately upon starting as an attending.

How much do oncologists typically owe in student loans? According to AAMC 2023 data, the median medical school graduate who borrowed started at $200,000. After 6–8 years of training with interest accrual on IBR, oncology attendings typically begin their careers with $280,000–$320,000 in outstanding federal loan balances.

Is it worth refinancing oncology student loans if rates are high? Yes, in most cases. Even at 6–7% interest rates, refinancing to a 5–7 year term on a $300,000 balance generates significantly less total interest than 20 years of IBR payments at an oncology attending salary. The key is refinancing only after confirming you're at a for-profit employer with no PSLF path.

Run Your Own Numbers

Every physician's debt situation is different. Use the MedDebt Calculator to model your exact repayment strategy — PSLF vs. aggressive payoff vs. refinancing — with your actual loan balance, specialty, and income.

It's free, takes 2 minutes, and shows you net worth projections by year.

Disclosure: This article is for informational purposes only and does not constitute financial, legal, or tax advice. Loan program details change — always verify current rules on studentaid.gov. MedDebt may earn a referral commission if you refinance through links on this site.